CHMP Recommends Novo’s Frehemgo for Haemophilia A

EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion at its 14-17 September 2026 plenary meeting recommending EU marketing authorization for Novo Nordisk’s Frehemgo (denecimig), a bispecific antibody the company describes as the first factor VIIIa mimetic, for preventing or reducing bleeding episodes in adults and children with haemophilia A. Frehemgo was one of twelve new medicines CHMP recommended at the meeting, alongside eleven opinions extending the indications of already-approved drugs. The European Commission, not CHMP, makes the binding authorization decision, typically within about two months of a positive opinion.

What CHMP actually decided

A CHMP positive opinion is a scientific recommendation, not a marketing authorization. The committee reviews a sponsor's full dossier — nonclinical data, clinical trials, manufacturing information, proposed labeling — and votes on whether to recommend authorization to the European Commission, which holds the actual decision-making authority for EU-wide approvals. The Commission's decision typically follows within roughly two months and, in the large majority of cases, follows the committee's recommendation. Frehemgo's positive opinion at the 14-17 September plenary starts that clock; Novo Nordisk has already indicated a target launch window, in the first EU countries during the fourth quarter of 2026, that assumes the Commission decision arrives on the customary schedule.

A new mechanism, and a dosing pitch built around it

Denecimig is a bispecific antibody, the same broad class as emicizumab (marketed as Hemlibra), which has reshaped haemophilia A prophylaxis over the past several years by replacing factor VIII replacement with an antibody that mimics part of its clotting function. Novo Nordisk positions Frehemgo as mechanistically distinct — a factor VIIIa mimetic, rather than a factor VIII-bridging bispecific — and built its label pitch around dosing flexibility: a single pre-filled pen supporting monthly, every-two-week, or weekly administration, letting physicians and patients choose an interval rather than being fixed to one schedule. The FRONTIER 5 data, showing no new safety signal in patients switched directly from emicizumab to denecimig, is aimed squarely at the existing base of bispecific-antibody patients that a new entrant would need to draw from or accommodate.

One of twelve: a routine plenary, one non-routine drug

Frehemgo's recommendation arrived alongside a typically busy CHMP plenary: twelve new medicines recommended in total, including Alexion's Klygefa (gefurulimab) for generalised myasthenia gravis, Corcept Therapeutics' Lifyorli (relacorilant) for platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer, Incyte's Povofortay (povorcitinib) for moderate-to-severe hidradenitis suppurativa, Sanofi's VaxRabeo rabies vaccine, and Zeydovio (glepaglutide) for short bowel syndrome, plus two biosimilars and two generics. Eleven further opinions extended the indications of already-marketed drugs. For RA teams tracking the EU pipeline, the volume is a reminder that a single monthly plenary routinely clears a dozen or more products in parallel — keeping pace with CHMP's cadence is less about any one meeting and more about a standing monitoring process.

Frequently asked questions

What did CHMP recommend?

At its 14-17 September 2026 plenary meeting, EMA's Committee for Medicinal Products for Human Use adopted a positive opinion recommending EU marketing authorization for Novo Nordisk's Frehemgo (denecimig) to prevent or reduce bleeding episodes in adults and children with haemophilia A, with or without inhibitors.

What is new about Frehemgo?

Novo Nordisk describes it as the first factor VIIIa-mimetic bispecific antibody, offering monthly, once-every-two-weeks, or weekly prophylactic dosing in a single pre-filled pen. It is a different mechanism from existing bispecific prophylaxis therapies for haemophilia A.

What clinical evidence backs the opinion?

The FRONTIER trial program. FRONTIER 2 showed a significant reduction in annualized bleeding rate versus prior clotting-factor prophylaxis or on-demand treatment. FRONTIER 3 reported consistent results in pediatric patients. FRONTIER 5 found no new safety signals in patients switched directly from emicizumab, an existing bispecific antibody, to denecimig.

Does the CHMP opinion mean Frehemgo is approved?

Not yet. A CHMP positive opinion is a recommendation to the European Commission, which makes the binding EU-wide marketing authorization decision, typically within about two months of the opinion. Novo Nordisk has said it expects to launch Frehemgo in the first European countries in the fourth quarter of 2026 and more broadly across the EU starting in early 2027.